Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

83P - Development of steroid-refractory graft-versus-host disease in a patient with Hodgkin lymphoma treated with nivolumab before allogeneic hematopoietic stem cells transplantation

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Beynarovich Anastasiya

Citation

Annals of Oncology (2020) 31 (suppl_7): S1441-S1451. 10.1016/annonc/annonc392

Authors

B. Anastasiya

Author affiliations

  • Pavlov First Saint Petersburg State Medical University, Saint-Petersburg/RU
More

Abstract 83P

Background

Graft-versus-host disease (GVHD) is the most frequent complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and a significant cause of morbidity and mortality. Systemic steroid therapy is the basis of treatment for GVHD; however, some patients are refractory to treatment. There are concerns about an increased incidence of GVHD for patients with Hodgkin lymphoma (HL) previously treated with immune checkpoint inhibitors (ICIs). In addition, data about patients with steroid-refractory form of GVHD in this setting is limited. The aim of this study was to define incidence of GVHD and investigate current treatment options for patients with rrHL after bridge therapy with immune checkpoint inhibitors.

Methods

We retrospectively evaluated the results of allo-HSCT in 23 adult patients after ICIs -based therapy. Complete response to PD-1 therapy before allo-HSCT was documented in 9 patients (39%), partial response- in 6 patients (26%), 5 patients (22%) had disease progression and 3 patients (13%) were transplanted in indeterminate response. All patients received reduced-intensity conditioning regimenand PTCy-based GvHD prophylaxis.

Results

At the time of analysis, median follow-up was 14 months.The 1-year OS and EFS were 83% and 74% respectively. Out of the 20 patients with engraftment 15 patients developed acute GVHD. Four patients had a steroid-refractory aGVHD. As a second line of therapy patients received single-agent ruxolitinib (n=2) or combination of ruxolitinib with extracorporeal photopheresis (ECP) and steroids (n=2) and all patients achieved complete response. Ten patients had chronic GVHD. Four patients with steroid-refractory cGVHD achieved CR receiving combined immunosuppressive therapy (ruxolitinib and steroids,n=2;steroids+cyclosporine A and ECP,n=2). One patient with severe skin cGVHD achieved PR on combination of steroids and ECP, another patient with a severe refractory cGVHD achieved stabilization only with third line of therapy (ruxolitinib+imatinib).

Conclusions

Introduction of target agents for srGVHD might ameliorate GVHD-related mortality and morbidity in rrHL patients after ICIs.

Legal entity responsible for the study

B. Anastasiya.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings